Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare Rx “donut hole” coverage demo

Executive Summary

Medicare Part D supplemental drug coverage demonstration project allowing drug plans to cover the "donut hole" is announced in Feb. 25 1Federal Register notice. Prescription drug plans offering enhanced alternative coverage would receive a capitated drug reinsurance payment instead of specific reinsurance payments of 80% of drug costs after a beneficiary has reached the catastrophic coverage level. The plan may fill the "donut hole" in part or in its entirety and must provide catastrophic drug coverage. Medicare Advantage drug plans may choose to fill the coverage gap using Part A or Part B rebate dollars. Health insurers worked with the Centers for Medicare & Medicaid Services to have the demo project developed (2"The Pink Sheet" Jan. 24, 2005, p. 14)...

You may also be interested in...



“Donut Hole” Waiver Planned By CMS; Merck Legacy Helps Medco In Part D

CMS is developing a waiver process that would provide up-front, capitated catastrophic coverage payments to Medicare Part D sponsors that design plans to fill in the "donut hole" coverage gap

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS045435

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel